De Las Cuevas Carlos, de Leon Victoria C, Blasco-Fontecilla Hilario, Baca-García Enrique, Sagud Marina, Sanz Emilio J, de Leon Jose
Department of Internal Medicine, Dermatology, and Psychiatry and Instituto Universitario de Neurociencia (IUNE), Universidad de La Laguna, La Laguna, Spain.
Department of Psychiatry, Washington University School of Medicine in St Louis, St Louis, MO, USA.
Expert Opin Drug Saf. 2024 Sep 11:1-11. doi: 10.1080/14740338.2024.2399094.
In the United States, clozapine was first approved for treatment-resistant schizophrenia and then for suicidality in schizophrenia psychoses. Systematic reviews support clozapine's anti-suicidal effect, but the forensic literature stresses its lethality during overdoses.
Clozapine reports to the international pharmacovigilance database (VigiBase) were analyzed for suicidal ideation, suicide attempts, intentional overdose, and completed suicides from introduction to 1 January 2024. VigiBase uses the information component (IC) as a disproportionality analysis.
The clozapine ICs (range: other antipsychotics) were: 1) suicidal ideation IC = 0.570 with IC = 0.454 to IC = 0.680 (IC = 3.568 for aripiprazole and 1.729 for risperidone), 2) suicide attempt IC = 1.428 with IC = 1.323 to IC = 1.529 (IC = 4.150 for quetiapine and 2.968 for risperidone), 3) intentional overdose: IC = 0.995 with IC = 0.864 to IC = 1.120 (IC = 4.080 for quetiapine and 1.957 for aripiprazole), and 4) completed suicide IC = 1.133 with IC = 1.026 to IC = 1.235 (IC = 4.648 for quetiapine and 2.160 for risperidone). In summary, all clozapine ICs were significantly lower. We found 2391 clozapine-treated patients on the suicidality spectrum (627 cases with suicidal ideation, 752 with suicide attempt, 488 with intentional overdose, and 731 with completed suicide) but many were taking other antipsychotics. The most frequent reporting countries were the United States, the United Kingdom, and Croatia.
This pharmacovigilance study, with all its inherent limitations, provides independent proof, not overlapping with prior literature, that clozapine may have specific strong anti-suicidal effects that do not appear to be present in other antipsychotics. Further VigiBase studies are needed to compare the lethality of an intentional overdose of clozapine (14.3%) with other antipsychotics.
在美国,氯氮平最初被批准用于治疗难治性精神分裂症,随后又被批准用于治疗精神分裂症性精神病中的自杀行为。系统评价支持氯氮平的抗自杀作用,但法医学文献强调其过量服用时的致死性。
对国际药物警戒数据库(VigiBase)中自氯氮平引入至2024年1月1日期间有关自杀意念、自杀未遂、故意过量服药及自杀死亡的报告进行分析。VigiBase使用信息成分(IC)进行不成比例分析。
氯氮平的IC值(范围:其他抗精神病药物)如下:1)自杀意念IC = 0.570,IC范围为0.454至0.680(阿立哌唑的IC = 3.568,利培酮的IC = 1.729);2)自杀未遂IC = 1.428,IC范围为1.323至1.529(喹硫平的IC = 4.150,利培酮的IC = 2.968);3)故意过量服药:IC = 0.995,IC范围为0.864至1.120(喹硫平的IC = 4.080,阿立哌唑的IC = 1.957);4)自杀死亡IC = 1.133,IC范围为1.026至1.235(喹硫平的IC = 4.648,利培酮的IC = 2.160)。总之,氯氮平的所有IC值均显著更低。我们发现2391例接受氯氮平治疗的患者处于自杀行为谱中(627例有自杀意念,752例有自杀未遂,488例有故意过量服药,731例有自杀死亡),但许多患者同时服用其他抗精神病药物。报告最多的国家是美国、英国和克罗地亚。
这项药物警戒研究尽管存在所有固有的局限性,但提供了独立的证据,与先前的文献不重叠,表明氯氮平可能具有特定的强大抗自杀作用,而其他抗精神病药物似乎没有这种作用。需要进一步通过VigiBase研究来比较氯氮平故意过量服药的致死率(14.3%)与其他抗精神病药物的致死率。